SpringerProtocols: Abstract: Tissue Factor/VIIa in Thrombosis and Cancer

Tissue Factor/VIIa in Thrombosis and Cancer

By: Shaker A. Mousa²

Abstract

Full Text

Download PDF (219K)

Tissue factor (TF) is a transmembrane glycoprotein that functions as a receptor and cofactor for activated factor VII (factor VIIa) to initiate blood coagulation. Although TF has been characterized best for its role in blood coagulation, recent studies have suggested a role for the molecule in physiologic processes that are distinct from hemostasis. Recently, this molecule has been shown to induce cellular signaling and promote angiogenesis and tumor metastasis (1–6).

Affiliation(s): (2) Albany College of Pharmacy, Albany, NY

Book Title: Anticoagulants, Antiplatelets, and Thrombolytics

Series: Methods in Molecular Medicine | Volume: 93 | Pub. Date: Nov-03-2003 | Page Range: 119-132 | DOI: 10.1385/1-59259-658-4:119

Subject: Molecular Medicine

References

Download References

1.	Bromberg, M. E., Konigsberg, W. H., Madison, J. F., et al. (1995) Tissue factor promotes metastasis by a pathway independent of blood coagulation. Proc. Natl. Acad. Sci. USA 92, 8205–8209.

2.	Bromberg, M. E., Sundaram, R., Homer, R. J., et al. (1999) Role of tissue factor in metastasis: function of the cytoplasmic and extracellular domains of the molecule. Thromb. Haemostasis 82, 88–92.

3.	Bromberg, M. E., Bailly, M. A., and Konigsberg, W. H. (2001) Role of protease-activated receptor 1 in tumor metastasis promoted by tissue factor. Thromn. Haemostasis 86, 1210–1214.

4.	Mousa, S. A. (2002) Anticoagulants in thrombosis and cancer: the missing link. Semin. Thromb. Hemost. 28(1), 45–52.

5.	Mousa, S. A. and Mohamed, S. (2001) Anti-angiogenesis efficacy & mechanism of the low molecular weight heparin, tinzaparin and tissue factor pathway inhibitor (TFPI): potential anti-cancer benefits. Thromb. Haemostasis P1981.

6.	Amirkhosravi, A., Francis, J., and Mousa, S. A. (2001) Anti-metastatic effect of low molecular weight heparin and tissue factor pathway inhibitor. Thromb. Haemostasis P1409.

7.	Nemerson, Y. (1988) Tissue factor and hemostasis. Blood 71, 1–8.

8.	Paborsky, L. R., Caras, I. W., and Fisher, K. L. (1991) Lipid association, but not the transmembrane domain, is required for tissue factor activity. Substitution of the transmembrane domain with a phosphatidylinositol anchor. J. Biol. Chem. 266, 21,911–21,916.

9.	Zioncheck, T. F., Roy, S., and Behar, G. A. (1992) The cytoplasmic domain of tissue factor is phosphorylated by a protein kinase C-dependent mechanism. J. Biol. Chem. 267, 3561–3564.

10.	Mody, R. S. and Carson, S. D. (1997) Tissue factor cytoplasmic domain peptide is multiply phosphorylated in vitro. Biochemistry 36, 7869–7875.

11.	Bazan, J. F (1990) Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. USA 87, 6934–6938.

12.	Muller, Y. A., Ultsch, M. N., and deVos, A. M. (1996) The crystal structure of the extracellular domain of human tissue factor refined to 1.7 A resolution. J. Mol. Biol. 256, 144–159.

13.	Broze, G. J. (1998) The tissue factor pathway of coagulation, in Thrombosis and Hemorrhage, Baltimore, MD, Williams and Wilkins, pp. 77–104.

14.	Camerer, E., Rottingen, J. A., Iversen, J. G., et al. (1996) Coagulation factor VII and coagulation factor X induce Ca²⁺ oscillations in Madin-Darby canine kidney cells only when proteolytically active. J. Biol. Chem. 271, 29,034–29,042.

15.	Masuda, M., Nakamura, S., Murakami, T, et al. (1996) Association of tissue factor with a gamma-chain homodimer of the IgE receptor-type I in cultured human monocytes. Eur. J. Immunol. 26, 2529–2532.

16.	Poulsen, L. K., Jacobsen, N., Sorensen, N. C. H., et al. (1998) Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor. J. Biol. Chem. 273, 6228–6232.

17.	Versteeg, H. H., Hoedemaeker, I., Diks, S. H., et al. (2000) FactorVIIa/tissue factor-induced signaling via activation of Src-like kinases, phosphatidylinositol 3-kinase, and Rac. J. Biol. Chem. 275, 28,750–28,756.

18.	Pendurthi, U. R., Alok, D., and Rao, L. V M. (1997) Binding of factor VIIa to tissue factor induces alterations in gene expression in human fibroblast cells: up-regulation of poly(A) polymerase. Proc. Natl. Acad. Sci. USA 94, 12,598–12,603.

19.	Ollivier, V., Bentolia, S., Chabbat, J., et al. (1998) Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood 91, 2698–2703.

20.	Taniguchi, T., Kakkar, A. K., Tuddenham, E. G. D., et al. (1998) Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. Cancer Res. 58, 4461–4467.

21.	Siegbahn, A., Johnell, M., Rorsman, C., et al. (2000) Binding of factor VIIa to tissue factor on human fibroblasts leads to activation of phopholipase C and enhanced PDGF-BB-stimulated chemotaxis. Blood 96, 3452–3458.

22.	Camerer, E., Rottingen, J.-A., Gjernes, E., Larsen, K., Skartlien, A. H., Iversen, J.-G., et al. (1999) Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene. J. Biol. Chem. 274, 32,225–32,233.

23.	Pendurthi, U. R., Allen, K. E., Ezban, M., et al. (2000) Factor VIIa and thrombin induce the expression of Cyr61 and connective tissue growth factor, extracellular matrix signaling proteins that could act as possible downstream mediators in factor VIIa-tissue factor-induced signal transduction. J. Biol. Chem. 14, 632–641.

24.	Wojtukiewicz, M., Zacharski, L., Memoli, V., et al. (1990) Fibrinogen-fibrin transformation in situ in renal cell carcinoma. Anticancer Res. 10, 579–582.

25.	Zacharski, L., Wojtukiewicz, M., Costantini, V., et al. (1992) Pathways of coagulation/fibrinolysis activation in malignancy. Sem. Thromb. Hemost. 18, 104–116.

26.	Zacharski, L., Henderson, W., Rickles, F., et al. (1984) Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck and prostate. Cancer 53, 2046–2052.

27.	Trousseau, A. (1865) Phlegmasia alba dolens. Clinique medicale de ľhotel-dieu de Paris. New Sydenham Society, London 3, 94.

28.	Zacharski, L. and Meehan, K. (1993) Anticoagulants and cancer therapy. The Cancer Journal 6, 16–20.

29.	Sorensen, H., Mellemkjaer, L., Olsen, J., and Baron, J. (2000) Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med. 343, 1846–1850.

30.	Lebeau, B., Chastang, C., Brechot, J.-M., et al. (1994) Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 74, 38–45.

31.	Chahinian, A., Propert, K., Ware, J., et al. (1989) A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J. Clin. Oncol. 7, 993–1002.

32.	Thornes, R. (1983) Coumarins, melanoma and cellular immunity, in Protective Agents in Cancer (McBrien, D. and Slator, T., eds.), London, Academic Press, pp. 43–56.

33.	Levine, M., Hirsh, J., Gent, M., et al. (1994) Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343, 886–889.

34.	Pinedo, H., Verheul, H., D’Amato, R., and Folkman, J. (1998) Involvement of platelets in tumour angiogenesis? Lancet 352, 1775–1777.

35.	Ruf, W. and Edgington, T. S. (1991) An anti-tissue factor monoclonal antibody which inhibits TF-VIIa complex is a potent anticoagulant in plasma. Thromb. Haemostasis 66, 529–533.

36.	Fiore, M. M., Neuenschwander, P. F., and Morrissey, J. H. (1992) An unusual antibody that blocks tissue factor/factor VIIa function by inhibiting cleavage only of macromolecular substrates. Blood 80, 3127–3134.

37.	Wun, T. C., Kretzmer, K. K., Palmier, M. O., et al. (1992) Comparison of recombinant tissue factor pathway inhibitors expressed in human SK hepatoma, mouse C127, baby hamster kidney, and Chinese hamster ovary cells. Thromb. Haemostasis 68, 54–59.

38.	Kuenen, B. C., Levi, M., Meijers, J. C., Kakkar, A. K., van Hinsbergh, V. W., Kostense, P. J., et al. (2002) Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler. Thromb. Vase. Biol. 22(9), 1500–1505.

39.	Mousa, S. A., Bozarth, J., Larnkjaer, A., and Johanson, K. (2000) Vascular effects of heparin molecular weight fractions and LMWH on the release of TFPI from human endothelial cells. Blood 16(11), 59, 3928.

40.	Marutsuka, K., Hatakeyama, K., Sato, Y., Yamashita, A., Sumiyoshi, A., and Asada, Y (2002) Protease-activated receptor 2 (PAR2) mediates vascular smooth muscle cell migration induced by tissue factor/factor Vila complex. Thromb. Res. 107(5), 271–276.

41.	Siegbahn, A., Johnell, M., Rorsman, C., Ezban, M., Heldin, C. H., and Ronnstrand, L. (2000) Binding of factor Vila to tissue factor on human fibroblasts leads to activation of phospholipase C and enhanced PDGF-BB-stimulated chemotaxis. Blood 96(10), 3452–3458.

42.	Abe, K., Shoji, M., Chen, J., Bierhaus, A., Danave, I., Micko, C., et al. (1999) Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc. Natl. Acad. Sci. USA 96(15), 8663–8668.

43.	Takano, S., Tsuboi, K., Tomono, Y., Mitsui, Y., and Nose, T. (2000) Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br. J. Cancer 82(12), 1967–1973.

44.	Seto, S., Onodera, H., Kaido, T., Yoshikawa, A., Ishigami, S., Arii, S., et al. (2000) Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer 88(2), 295–301.

45.	Dupont, E., Falardeau, P., Mousa, S. A., Dimitriadou, V., Pepin, M. C, Wang, T., et al. (2002) Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin. Exp. Metastasis 19(2), 145–153.

46.	Kim, S., Mousa, S. A., and Varner, J. (2000) Requirement of integrin α₅β₁ and its ligand fibronectin in angiogenesis. Am. J. Pathol. 156, 1345–1362.

47.	Colman, R. W., Pixley, R. A., Sainz, I. M., Song, J. S., Isordia-Salas, Mohamed, S., et al. (2003) Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecular-weight kininogen. J. Thromb. Haemostasis 1(1), 164–173.

48.	Van Waes, C., Enamorado, D., Hecht, I., Sulica, L., Chen, Z., Batt, D., et al. (2000) Effects of the novel αv integrin antagonist SM256 and cis-platinum on growth of murine squamous cell carcinoma PAMLY8. Int. J. Oncol. 16(6), 1189–1195.

49.	Ali, S., O’Dounell, A., Balu, D., Pohl, M., Seyler, M., Mohamed, S., et al. (2000) Estrogen receptor-α in the inhibition of cancer growth and angiogenesis. Cancer Res. 60, 7094–7098.

50.	Luna, J., Tobe, T., Mousa, S. A., Reilly, T., and Campochiaro, P. (1996) Antagonist of Integrin α_vβ₃ Inhibit Retinal Neovascularization in Murine Model. Lab. Investig. 75(4), 563–573.

51.	Chen, Z., Malhotra, P., Thomas, G., Ondrey, F., Duffey, D., Smith, C., et al. (1999) Expression of pro-inflammatory and pro-angiogenic cytokines in patients with head and neck cancer. Clinical Cancer Res. (5), 1369–1379.

Comments (Loading...)

Post comment/View all comments